Neumora Therapeutics (NMRA) News Today $1.92 -0.01 (-0.26%) As of 12:22 PM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends All Sources Trusted Sources MarketBeat Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha TalkMarkets The Street TipRanks The Wall Street Journal Wall Street Zen Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent January 2025 December 2024 November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 Time Period Brokerages Set Neumora Therapeutics, Inc. (NASDAQ:NMRA) Target Price at $16.50Shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned an average rating of "Moderate Buy" from the seven analysts that are covering the company, MarketBeat reports. Two research analysts have rated the stock with a hold rating and five have issued a buy rating onJanuary 30 at 1:18 AM | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Given Consensus Rating of "Moderate Buy" by BrokeragesShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned a consensus recommendation of "Moderate Buy" from the seven ratings firms that are presently covering the company, Marketbeat reports. Two research analysts have rated the stock with a hold recommendation and fiJanuary 27 at 4:42 AM | marketbeat.comWilliam Blair Reiterates Outperform Rating for Neumora Therapeutics (NASDAQ:NMRA)William Blair reissued an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday.January 16, 2025 | marketbeat.comNeumora Therapeutics' (NMRA) Outperform Rating Reiterated at William BlairWilliam Blair restated an "outperform" rating on shares of Neumora Therapeutics in a report on Wednesday.January 15, 2025 | marketbeat.comBiotech Stock Roundup: NMRA Plunges on Study Failure, HOTH, VIR Soar on Study Data & MoreJanuary 10, 2025 | msn.comNeumora Therapeutics Target of Unusually High Options Trading (NASDAQ:NMRA)Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the recipient of some unusual options trading activity on Monday. Traders bought 5,936 call options on the stock. This represents an increase of approximately 45% compared to the typical daily volume of 4,096 call options.January 6, 2025 | marketbeat.comBank of America Cuts Neumora Therapeutics (NASDAQ:NMRA) Price Target to $7.00Bank of America reduced their price target on Neumora Therapeutics from $22.00 to $7.00 and set a "buy" rating for the company in a report on Monday.January 6, 2025 | marketbeat.comNeumora Therapeutics price target lowered to $7 from $22 at BofAJanuary 6, 2025 | markets.businessinsider.comWhat is William Blair's Estimate for NMRA FY2029 Earnings?Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Analysts at William Blair issued their FY2029 earnings estimates for Neumora Therapeutics in a research report issued to clients and investors on Thursday, January 2nd. William Blair analyst M. Minter expects that the company will earn $1.4January 6, 2025 | marketbeat.comNeumora shares look oversold after 80% drop, says MizuhoJanuary 4, 2025 | markets.businessinsider.comHold Rating for Neumora Therapeutics Amid Disappointing Phase 3 Trial Results and High-Risk Pipeline DependencyJanuary 4, 2025 | markets.businessinsider.comNeumora Nosedives 80% At Pre-Market on Failed Depression Drug TrialJanuary 3, 2025 | msn.comBuy Rating Maintained for Neumora Therapeutics Due to Promising MDD Trial Results and Strong Financial PositionJanuary 3, 2025 | markets.businessinsider.comNeumora drops as depression therapy fails in late-stage trialJanuary 3, 2025 | seekingalpha.comNeumora Therapeutics’ stock craters after trial of major depressive disorder fails to meet main goalsJanuary 3, 2025 | msn.comNeumora Therapeutics: Tanking On Disastrous MDD Data, Bounce Back UnlikelyJanuary 3, 2025 | seekingalpha.comNeumora Therapeutics (NASDAQ:NMRA) Given Buy Rating at HC WainwrightHC Wainwright reissued a "buy" rating and issued a $30.00 price objective on shares of Neumora Therapeutics in a research note on Friday.January 3, 2025 | marketbeat.comNeumora Therapeutics’ navacaprant did not meet primary endpoint in depressionJanuary 3, 2025 | markets.businessinsider.comResults are in for a new depression drug trial, and they're cratering this stockJanuary 3, 2025 | msn.comNeumora Therapeutics (NASDAQ:NMRA) Hits New 1-Year Low - Time to Sell?Neumora Therapeutics (NASDAQ:NMRA) Sets New 12-Month Low - Here's What HappenedJanuary 2, 2025 | marketbeat.comNeumora Therapeutics, Inc. Investigated for Securities Fraud Violations - Contact the DJS Law Group to Discuss Your Rights - NMRAJanuary 2, 2025 | businesswire.comNeumora Therapeutics (NASDAQ:NMRA) Rating Lowered to "Sector Perform" at Royal Bank of CanadaRoyal Bank of Canada cut Neumora Therapeutics from an "outperform" rating to a "sector perform" rating and reduced their target price for the company from $29.00 to $4.00 in a research note on Thursday.January 2, 2025 | marketbeat.comNeumora Therapeutics shares plummet as Phase 3 depression drug trial disappointsJanuary 2, 2025 | proactiveinvestors.comNeumora Therapeutics Stock Tanks as Its Depression Drug Misses GoalsJanuary 2, 2025 | investopedia.comNeumora Therapeutics Stock Crashes 83% After Depression Drug FlopsJanuary 2, 2025 | investors.comNeedham & Company LLC Reiterates "Buy" Rating for Neumora Therapeutics (NASDAQ:NMRA)Needham & Company LLC reaffirmed a "buy" rating and set a $23.00 price target on shares of Neumora Therapeutics in a report on Thursday.January 2, 2025 | marketbeat.comNeumora Therapeutics' depression drug fails to meet main goal of late-stage studyJanuary 2, 2025 | reuters.comNeumora Therapeutics Reports Data from KOASTAL-1 Study of Navacaprant in Major Depressive DisorderJanuary 2, 2025 | globenewswire.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Average Rating of "Moderate Buy" from AnalystsShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have been assigned a consensus rating of "Moderate Buy" from the six research firms that are presently covering the company, MarketBeat reports. One investment analyst has rated the stock with a hold rating and five have given aJanuary 2, 2025 | marketbeat.comNeumora Therapeutics (NASDAQ:NMRA) Shares Down 4.3% - What's Next?Neumora Therapeutics (NASDAQ:NMRA) Shares Down 4.3% - Here's What HappenedDecember 31, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Barclays PLCBarclays PLC raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 352.9% in the 3rd quarter, according to its most recent filing with the SEC. The fund owned 129,210 shares of the company's stock after purchasing an additional 100,678 shares during the period. Barclays PLCDecember 28, 2024 | marketbeat.comNeumora Therapeutics Inc put volume heavy and directionally bearishDecember 28, 2024 | markets.businessinsider.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Bought by Geode Capital Management LLCGeode Capital Management LLC increased its position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 54.0% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 1,979,847 shares of the company's stocDecember 27, 2024 | marketbeat.comThis Is What Whales Are Betting On Neumora TherapeuticsDecember 26, 2024 | benzinga.comNeumora Therapeutics (NASDAQ:NMRA) Shares Up 7.2% - Here's WhyNeumora Therapeutics (NASDAQ:NMRA) Trading Up 7.2% - Time to Buy?December 26, 2024 | marketbeat.comNeumora: Koastal-1 Readout For MDD Treatment Is First Study On DeckDecember 24, 2024 | seekingalpha.comNeumora Therapeutics (NASDAQ:NMRA) Shares Down 3% - Should You Sell?Neumora Therapeutics (NASDAQ:NMRA) Stock Price Down 3% - Should You Sell?December 24, 2024 | marketbeat.comNeumora Therapeutics Sees Unusually High Options Volume (NASDAQ:NMRA)Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) was the recipient of some unusual options trading on Monday. Stock investors purchased 3,760 put options on the company. This represents an increase of approximately 47% compared to the average daily volume of 2,556 put options.December 23, 2024 | marketbeat.comState Street Corp Has $23.66 Million Stock Holdings in Neumora Therapeutics, Inc. (NASDAQ:NMRA)State Street Corp increased its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 65.3% during the third quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The firm owned 1,790,707 shares of the company's stock after aDecember 23, 2024 | marketbeat.comAnalysts Set Expectations for NMRA Q1 EarningsNeumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) - Equities research analysts at HC Wainwright issued their Q1 2025 earnings estimates for Neumora Therapeutics in a research report issued on Monday, December 16th. HC Wainwright analyst D. Tsao anticipates that the company will post earningsDecember 18, 2024 | marketbeat.comPositive Outlook for Neumora Therapeutics Amid Key Milestones and Competitive EdgeDecember 17, 2024 | markets.businessinsider.comNeumora Therapeutics (NASDAQ:NMRA) Earns Buy Rating from HC WainwrightHC Wainwright reaffirmed a "buy" rating and set a $30.00 target price on shares of Neumora Therapeutics in a research note on Monday.December 16, 2024 | marketbeat.comPoint72 Asset Management L.P. Makes New $1.10 Million Investment in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Point72 Asset Management L.P. acquired a new stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the third quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 83,077 shares of the company's stoDecember 11, 2024 | marketbeat.comCharles Schwab Investment Management Inc. Raises Stock Position in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Charles Schwab Investment Management Inc. raised its stake in shares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 139.7% during the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The institutional investor ownDecember 10, 2024 | marketbeat.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Receives Consensus Rating of "Moderate Buy" from AnalystsShares of Neumora Therapeutics, Inc. (NASDAQ:NMRA - Get Free Report) have received an average rating of "Moderate Buy" from the seven brokerages that are presently covering the company, Marketbeat Ratings reports. Two equities research analysts have rated the stock with a hold rating and five haveDecember 8, 2024 | marketbeat.comRBC Capital Sticks to Its Buy Rating for Neumora Therapeutics, Inc. (NMRA)December 6, 2024 | markets.businessinsider.comNeumora Therapeutics, Inc. (NASDAQ:NMRA) Shares Acquired by Wexford Capital LPWexford Capital LP raised its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 90.1% during the 3rd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor owned 217,879 shares of the company's stock after buying an additional 103,285 sharesDecember 6, 2024 | marketbeat.comFmr LLC Trims Stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA)Fmr LLC lessened its stake in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) by 10.1% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The institutional investor owned 7,749,156 shares of the company's stock after selliDecember 5, 2024 | marketbeat.comCerity Partners LLC Acquires Shares of 242,900 Neumora Therapeutics, Inc. (NASDAQ:NMRA)Cerity Partners LLC bought a new position in Neumora Therapeutics, Inc. (NASDAQ:NMRA - Free Report) in the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The firm bought 242,900 shares of the company's stock, valued at approximately $3,209,000. Cerity Partners LLCDecember 1, 2024 | marketbeat.comNeumora Therapeutics' (NMRA) "Outperform" Rating Reiterated at Royal Bank of CanadaRoyal Bank of Canada reaffirmed an "outperform" rating and issued a $29.00 target price on shares of Neumora Therapeutics in a research note on Friday.November 22, 2024 | marketbeat.com Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address NMRA Media Mentions By Week NMRA Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. NMRA News Sentiment▼0.230.76▲Average Medical News Sentiment NMRA News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. NMRA Articles This Week▼33▲NMRA Articles Average Week Get Neumora Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for NMRA and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies ANI Pharmaceuticals News Today Arvinas News Today Arcus Biosciences News Today Ocular Therapeutix News Today Syndax Pharmaceuticals News Today Calliditas Therapeutics AB (publ) News Today Aurinia Pharmaceuticals News Today Adaptive Biotechnologies News Today Collegium Pharmaceutical News Today Spyre Therapeutics News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:NMRA) was last updated on 1/30/2025 by MarketBeat.com Staff From Our Partners#1 Crypto of 2025Chris Rowe – the man who recommended Amazon in 1998… Bitcoin and Ethereum in 2017… And has spotted 44 diffe...True Market Insiders | SponsoredWhy Buffett, Griffin and 100 members of Congress are Piling into this One InvestmentThis isn't just another investment. It might be the last retirement stock you'll ever need. But this win...Behind the Markets | SponsoredIs Big Tech dead?China just threw a “$5.5 million” curveball called Deep Seek to Silicon Valley and the timing of it is no coin...Brownstone Research | SponsoredPlease take this warning seriously...I’m here to issue a stark warning to you about an unexpected $2 trillion shock that could impact every trader ...Timothy Sykes | SponsoredHot Stock Alert! Biotech innovator on the NYSE announces breakthrough antiviral therapyA revolutionary antiviral drug is here! This breakthrough could mean viruses are unlikely to escape treatment....Smallcaps Daily | SponsoredTexas approves new currencyRural Texas Town Ramps Up Global Currency War A small town has joined a radical $1.9 trillion attack on the...Stansberry Research | SponsoredVladimir Lenin was right…The Magnificent 7 could be in for a world of pain… And the insiders know it. It’s why Jeff Bezos just sold ...Porter & Company | SponsoredWill Elon trigger another AI flash crash?AI continues to dominate financial headlines in 2025...Altimetry | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Neumora Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Neumora Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free NMRA Stock Alerts